Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase I, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Patients With Unresectable, Advanced and/or Metastatic Solid Tumors, Including Pancreatic Cancer, That Are Positive for the TP53 R175H Mutation

Summary

The purpose of this phase I trial is to evaluate the safety and efficacy of NT-175 in HLA-A*02:01 patients with unresectable, advanced, and/or metastatic solid tumors, including pancreatic cancer, that are positive for the TP53 R175H mutation.

General Information

NCT#: NCT05877599
Study ID: NT-175-201
Trial Phase: Phase I

Trial Sponsor: Neogene Therapeutics
Therapies Used in This Trial: NT-175

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search